Theolytics is developing category changing oncolytic virus cancer therapies. The company is pioneering a phenotypic screening approach to the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population. Theolytics, which was founded in 2017 and is headquartered in Oxford, UK, is backed by international life sciences investors Taiho Ventures, Epidarex Capital, and M Ventures, as well as Oxford Science Innovation (OSI).
Theolytics, a biotechnology company harnessing viruses to combat disease, will release data on their proprietary systemic therapy for stromal-rich tumours at the 2022 International Oncolytic Virus Conference, and announce executive appointments.
2022/05/31Theolytics kick-starts a £1M project in collaboration with The University of Sheffield, supported by Innovate UK, to develop a novel therapy for multiple myeloma patients in need
2021/07/08Theolytics is harnessing viruses to combat cancer: transforming patients’ lives; through world leading science; with a great team.
